BPROAD Study: A Landmark Chinese Contribution to Global Cardiovascular Science
China Health Trip takes you through the latest medical breakthroughs in China, showcasing the possibilities of advanced healthcare. Read on for more insights.
BPROAD Study debuts at AHA meeting with groundbreaking findings
On November 16 2024, the BPROAD study (Blood Pressure Reduction Targets in Chinese Adults with Type 2 Diabetes), led by Professors Wang Weiqing, Bi Yufang, and Xu Yu from the National Clinical Research Center for Metabolic Diseases at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, was presented at the American Heart Association (AHA) Centennial Celebration and 2024 Scientific Sessions. Academician Ning Guang of the Chinese Academy of Engineering and President of Ruijin Hospital delivered the team’s findings as the opening presentation in the Late Breaking Science session. Simultaneously, the New England Journal of Medicine published the groundbreaking results online. This marks the first time a Chinese scholar in the field of metabolism has been invited to deliver the opening report in AHA’s Late Breaking Science session at its annual meeting.
BPROAD Study design and results: intensive blood pressure control significantly Reduces cardiovascular risk
The BPROAD study is a randomized, open-label, outcome-assessor-blinded, parallel-group clinical trial involving 12,821 patients aged 50 years or older with elevated systolic blood pressure and increased cardiovascular risk from 145 secondary and tertiary hospitals across mainland China.
The study demonstrated that among patients with type 2 diabetes and hypertension, lowering systolic blood pressure to below 120 mmHg, compared to below 140 mmHg, significantly reduced the relative risk of major cardiovascular events by 21%, provided that blood pressure and electrolyte levels were closely monitored during the use of multiple antihypertensive medications. The BPROAD study, which focuses on intensive versus standard blood pressure control in patients with type 2 diabetes and hypertension, is the largest randomized controlled trial to date evaluating blood pressure targets.
Intensive blood pressure control resolves controversy over targets for type 2 diabetes
Cardiovascular disease is the leading cause of death among patients with type 2 diabetes, making systolic blood pressure control critically important. However, global clinical guidelines remain divided on the optimal systolic blood pressure target for patients with type 2 diabetes and hypertension.
For instance, the ACCORD study, published in 2010, explored optimal blood pressure targets for patients with type 2 diabetes but found no difference in cardiovascular events between the intensive and standard treatment groups, partly due to limited statistical power and interactions with glycemic control. The SPRINT study revealed that intensive blood pressure control significantly reduced the relative risk of cardiovascular events by 27%, but it excluded patients with diabetes.
The BPROAD study now provides robust evidence that, in patients with type 2 diabetes, lowering systolic blood pressure to below 120 mmHg compared to below 140 mmHg significantly reduces the incidence of major cardiovascular events over a follow-up period of up to five years. The study also highlights the need to closely monitor hypotension and electrolyte disturbances during intensive treatment. For the first time, this research offers evidence-based medical support for a systolic blood pressure target below 120 mmHg in patients with type 2 diabetes, providing a Chinese solution to a critical global question regarding optimal blood pressure management in this population.
The theme and significance of AHA centennial scientific meeting
Founded in 1924, the AHA has evolved into a globally recognized leader in cardiovascular science and medicine. This year marks the AHA’s centennial, and its Scientific Sessions have become a premier event in the global cardiovascular academic community. The first Late Breaking Science session of this year’s meeting, themed “Celebrating a Century of Cardiovascular Science: From Prevention to Treatment and Cure,” reflects a century of achievement while envisioning a future focused on curing cardiovascular diseases.
BPROAD Study: A Landmark Chinese Contribution to Global Cardiovascular Science
China Health Trip takes you through the latest medical breakthroughs in China, showcasing the possibilities of advanced healthcare. Read on for more insights.
BPROAD Study debuts at AHA meeting with groundbreaking findings
On November 16 2024, the BPROAD study (Blood Pressure Reduction Targets in Chinese Adults with Type 2 Diabetes), led by Professors Wang Weiqing, Bi Yufang, and Xu Yu from the National Clinical Research Center for Metabolic Diseases at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, was presented at the American Heart Association (AHA) Centennial Celebration and 2024 Scientific Sessions. Academician Ning Guang of the Chinese Academy of Engineering and President of Ruijin Hospital delivered the team’s findings as the opening presentation in the Late Breaking Science session. Simultaneously, the New England Journal of Medicine published the groundbreaking results online. This marks the first time a Chinese scholar in the field of metabolism has been invited to deliver the opening report in AHA’s Late Breaking Science session at its annual meeting.
BPROAD Study design and results: intensive blood pressure control significantly Reduces cardiovascular risk
The BPROAD study is a randomized, open-label, outcome-assessor-blinded, parallel-group clinical trial involving 12,821 patients aged 50 years or older with elevated systolic blood pressure and increased cardiovascular risk from 145 secondary and tertiary hospitals across mainland China.
The study demonstrated that among patients with type 2 diabetes and hypertension, lowering systolic blood pressure to below 120 mmHg, compared to below 140 mmHg, significantly reduced the relative risk of major cardiovascular events by 21%, provided that blood pressure and electrolyte levels were closely monitored during the use of multiple antihypertensive medications. The BPROAD study, which focuses on intensive versus standard blood pressure control in patients with type 2 diabetes and hypertension, is the largest randomized controlled trial to date evaluating blood pressure targets.
Intensive blood pressure control resolves controversy over targets for type 2 diabetes
Cardiovascular disease is the leading cause of death among patients with type 2 diabetes, making systolic blood pressure control critically important. However, global clinical guidelines remain divided on the optimal systolic blood pressure target for patients with type 2 diabetes and hypertension.
For instance, the ACCORD study, published in 2010, explored optimal blood pressure targets for patients with type 2 diabetes but found no difference in cardiovascular events between the intensive and standard treatment groups, partly due to limited statistical power and interactions with glycemic control. The SPRINT study revealed that intensive blood pressure control significantly reduced the relative risk of cardiovascular events by 27%, but it excluded patients with diabetes.
The BPROAD study now provides robust evidence that, in patients with type 2 diabetes, lowering systolic blood pressure to below 120 mmHg compared to below 140 mmHg significantly reduces the incidence of major cardiovascular events over a follow-up period of up to five years. The study also highlights the need to closely monitor hypotension and electrolyte disturbances during intensive treatment. For the first time, this research offers evidence-based medical support for a systolic blood pressure target below 120 mmHg in patients with type 2 diabetes, providing a Chinese solution to a critical global question regarding optimal blood pressure management in this population.
The theme and significance of AHA centennial scientific meeting
Founded in 1924, the AHA has evolved into a globally recognized leader in cardiovascular science and medicine. This year marks the AHA’s centennial, and its Scientific Sessions have become a premier event in the global cardiovascular academic community. The first Late Breaking Science session of this year’s meeting, themed “Celebrating a Century of Cardiovascular Science: From Prevention to Treatment and Cure,” reflects a century of achievement while envisioning a future focused on curing cardiovascular diseases.